Novartis (NVS) Tops Q3 EPS by 4c Oct 25, 2016 08:44AM
Valeant Pharma (VRX) Announces Key Management Changes; Includes New Business Strategy SVP Aug 8, 2016 08:02AM
pSivida (PSDV) Appoints New Chief Medical Officer Aug 3, 2016 08:14AM
Glaukos Corporation (GKOS) Raising PT After Blowing Out Numbers - Cantor Fitzgerald Aug 2, 2016 08:36AM
Novartis (NVS) Tops Q2 EPS by 5c; Cautions on Entresto Spending Jul 19, 2016 08:28AM
View Older Stories

Jul 19, 2016 01:01AM Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jun 9, 2016 09:00AM Novelis Appoints Devinder Ahuja as Senior Vice President, Chief Financial Officer
May 25, 2016 09:23AM Novartis (NVS) Updates on Outlook into 'Meet Management' Event
May 25, 2016 05:43AM Novartis willing to sell Roche stake without demanding premium - CEO
May 25, 2016 01:00AM Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
May 23, 2016 12:16PM Novartis executive exodus complicates drugmaker's rebuilding job
May 17, 2016 12:04PM Novartis splits drugs business into two, pharma chief to leave
May 17, 2016 11:35AM Novartis (NVS) Splits Pharmaceuticals Division into Two Divisions; Announces Management Changes
May 17, 2016 11:30AM Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
May 17, 2016 10:30AM uStudio Named a “Hot Vendor” and Innovator in Enterprise Video
May 13, 2016 01:30AM ThromboGenics Business Update - Q1 2016
May 12, 2016 12:00PM EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial
Apr 27, 2016 02:00AM New Ocriplasmin Research Findings Presented
Apr 21, 2016 06:53AM Novartis (NVS) Misses Q1 EPS by 2c
Apr 21, 2016 01:01AM Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Apr 19, 2016 07:00PM Allergies and your eyes: What you need to know this spring by Brandpoint
Apr 12, 2016 11:00AM uStudio Founder Joins CTA Internet Video Initiative
Mar 31, 2016 01:00AM Novartis publishes updated 2015 segment financials reflecting new division structure
Mar 22, 2016 02:22PM Fitch Affirms Ratings of Novartis (NVS) Following Recent Review; Outlook Stable
Mar 10, 2016 09:00AM VisionCare Ophthalmic Technologies Announces Appointment of Industry Veteran, Thierry Clidiere, to its Board of Directors
Mar 1, 2016 02:23AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Feb 18, 2016 01:00AM Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Feb 11, 2016 01:59AM Publicis Groupe: 2015 Annual Results
Feb 1, 2016 10:48AM Leading Corporations Find EXHIBITORLIVE a Strategic Marketing Weapon as Attendance and Exhibition Increases
Jan 27, 2016 08:41AM Novartis (NVS) Misses Q4 EPS by 4c; Announces FY16 Strategy, Management Changes
Jan 27, 2016 01:00AM Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Jan 22, 2016 10:00AM Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration
Jan 14, 2016 08:00AM Novartis (NVS) Named Top Global Pharma Pick at Jefferies
Jan 13, 2016 01:35AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retino
Jan 11, 2016 07:00AM Ocular TherapeutixTM Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer
Nov 18, 2015 11:50AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 18, 2015 11:40AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 15, 2015 12:00PM Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
Nov 13, 2015 01:37AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 13, 2015 01:30AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 12, 2015 01:35AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 12, 2015 01:30AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 5, 2015 11:50AM ThromboGenics Business Update - Q3 2015
Nov 5, 2015 11:40AM ThromboGenics Business Update - Q3 2015
Oct 27, 2015 06:16AM Novartis (NVS) Misses Q3 EPS by 4c
View Older Stories